Xianjian Technology (01302.HK): Increased R&D investment, looking forward to continuous gains in the innovation pipeline
Xianjian Technology (01302.HK): Internationalization accelerates and enhances core products to continue to excel
Xianjian Technology (01302.HK): In line with expectations, innovative results continued to be harvested in the first half of the year
Xianjian Technology (01302.HK): Innovation and internationalization of established powerhouses of high-value consumables have entered a harvest period
Xianjian Technology (01302.HK): Steady growth in performance and abundant research pipelines
Xianjian Technology (1302.HK): China's leading minimally invasive intervention innovation enterprise
Xianjian Technology (01302.HK) Company Comment: 2021 Results Are in Line with Expectations, Adhere to Independent R&D and International Development
Xianjian Technology (01302.HK) 2021 Semi-Annual Report Review: Performance Exceeds Expectations and Steadily Implements the “Internationalization+Platformization” Innovative R&D Strategy
Xianjian Technology (01302.HK): Rapid release products for the left ventricle have been approved one after another
Xianjian Technology (01302.HK) Company Review: Semi-annual Report, Rapid Performance Growth, Adherence to Innovation and International Development Strategy
Xianjian Technology (01302.HK): Performance increased significantly in the first half of the year, strong technical strength, long-term improvement
Xianjian Technology (01302.HK) 2020 Annual Report Review: Performance Meets Expectations, Pipeline Enters Harvest Period
Xianjian Technology (01302.HK): Innovative Devices, Dark Horse, Interventional Consumables
Guoxin Securities: The DRGs pilot was further expanded to seize the three main lines of pharmaceutical investment
Xianjian Technology (01302.HK) announcement review: Small but beautiful among innovative devices, future growth can be expected
Xianjian Technology (01302.HK): Three business segments support performance growth, and products spread all over the world
Pioneer Technology (01302.HK): innovation leads the development of products into a comprehensive harvest period
First Health Technology (1302.HK): innovation wins
Xianjian Technology (01302.HK): The rapid growth of left atrial blockers and majority shareholder replacement brings new highlights
Xianjian Technology (01302.HK): Focus on interventional medical devices and actively enrich various product lines
No Data